20
May
2016
Genentech Enters the PD-L1 Arena, Theranos in Ashes & the ASCO PR Machine Revs Up
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.